(Q37252268)

19 August 2017

title

Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): DNA viruses (English)

1 reference

19 August 2017

Erik De Clercq

2

0 references

author name string

Hugh J Field

series ordinal

1

1 reference

19 August 2017

publication date

1 January 2008

1 reference

Antiviral Chemistry & Chemotherapy

19 August 2017

published in

1 reference

19 August 2017

volume

19

1 reference

19 August 2017

issue

2

1 reference

19 August 2017

page(s)

51-62

1 reference

Antiviral drugs in current clinical use.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Helicase primase: targeting the Achilles heel of herpes simplex viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

(E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Trisodium Phosphonoformate, a New Antiviral Compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Treatment of genital warts with an immune-response modifier (imiquimod).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Topical imiquimod: mechanism of action and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Effect of topical microbicides on infectious human immunodeficiency virus type 1 binding to epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Antiherpesviral and anticellular effects of 1-beta-D-arabinofuranosyl-E-5-(2-halogenovinyl) uracils

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus-infected adults. The Multinational Sorivudine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Metabolism of 5'-ether prodrugs of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Antiviral Potency of ST-246 on the Production of Enveloped Orthopoxviruses and Characterization of ST-246 Resistant Vaccinia, Cowpox and Camelpox Viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Antiviral L-nucleosides specific for hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

THERAPEUTIC ANTIVIRAL ACTION OF 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE IN HERPES SIMPLEX KERATITIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Efficacy of (-)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in African green monkeys infected with simian varicella virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900203

10.1177/095632020801900203

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference